These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 37446782

  • 1. Synthesis and Evaluation of 99mTc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.
    Lu K, Zhang C, Zhang Z, Kuo HT, Colpo N, Bénard F, Lin KS.
    Molecules; 2023 Jun 29; 28(13):. PubMed ID: 37446782
    [Abstract] [Full Text] [Related]

  • 2. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 29; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 3. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
    Kuo HT, Zhang Z, Zhang C, Merkens H, Tan R, Wong AAWL, Uribe CF, Bénard F, Lin KS.
    Theranostics; 2023 May 29; 13(13):4559-4573. PubMed ID: 37649602
    [Abstract] [Full Text] [Related]

  • 4. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT, Lin KS, Zhang Z, Zhang C, Merkens H, Tan R, Roxin A, Uribe CF, Bénard F.
    Theranostics; 2022 May 29; 12(14):6179-6188. PubMed ID: 36168623
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S.
    Bioorg Chem; 2020 Jun 29; 99():103743. PubMed ID: 32217372
    [Abstract] [Full Text] [Related]

  • 6. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [99mTc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [99mTc]Tc-EDDA/HYNIC-iPSMA in Prostate Cancer.
    Mamlins E, Scharbert L, Cardinale J, Krotov M, Winter E, Rathke H, Strodel B, Ankrah AO, Sathekge M, Haberkorn U, Kratochwil C, Giesel FL.
    Mol Imaging Biol; 2024 Feb 29; 26(1):81-89. PubMed ID: 38066252
    [Abstract] [Full Text] [Related]

  • 7. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer.
    Santos-Cuevas C, Ferro-Flores G, García-Pérez FO, Jiménez-Mancilla N, Ramírez-Nava G, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Davanzo J, Soldevilla-Gallardo I.
    Contrast Media Mol Imaging; 2018 Feb 29; 2018():5247153. PubMed ID: 30534027
    [Abstract] [Full Text] [Related]

  • 8. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.
    Santos-Cuevas C, Davanzo J, Ferro-Flores G, García-Pérez FO, Ocampo-García B, Ignacio-Alvarez E, Gómez-Argumosa E, Pedraza-López M.
    Nucl Med Biol; 2017 Sep 29; 52():1-6. PubMed ID: 28575794
    [Abstract] [Full Text] [Related]

  • 9. Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
    Xiao D, Duan X, Gan Q, Zhang X, Zhang J.
    Molecules; 2020 Nov 26; 25(23):. PubMed ID: 33256058
    [Abstract] [Full Text] [Related]

  • 10. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May 26; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 11. Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer.
    Yang H, Gao Z, Xu X, Liu C, Hu S, Zhang J, Song S.
    Ann Nucl Med; 2023 Jan 26; 37(1):60-69. PubMed ID: 36346503
    [Abstract] [Full Text] [Related]

  • 12. PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen.
    Cardinale J, Giesel FL, Wensky C, Rathke HG, Haberkorn U, Kratochwil C.
    J Nucl Med; 2023 Jul 26; 64(7):1069-1075. PubMed ID: 36759199
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer.
    Zhang J, Zhang J, Xu X, Lu L, Hu S, Liu C, Cheng J, Song S, Zhang Y, Shi LQ.
    Sci Rep; 2020 Mar 06; 10(1):4179. PubMed ID: 32144340
    [Abstract] [Full Text] [Related]

  • 14. Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.
    García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.
    Am J Nucl Med Mol Imaging; 2018 Mar 06; 8(5):332-340. PubMed ID: 30510850
    [Abstract] [Full Text] [Related]

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Mar 06; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and Radiolabeling of Glu-Urea-Lys with 99mTc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation as Prostate-Specific Membrane Antigen Inhibitor.
    Hatamabadi D, Joukar S, Shakeri P, Balalaie S, Yazdani A, Khoramjouy M, Mazidi SM, Kobarfard F, Mosayebnia M, Bozorgchami N, Ahmadi M, Ayyoubzadeh SM, Shahhosseini S.
    Cancer Biother Radiopharm; 2023 Sep 06; 38(7):486-496. PubMed ID: 37578479
    [Abstract] [Full Text] [Related]

  • 17. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y, Ando M, Watanabe H, Ono M.
    Ann Nucl Med; 2024 Oct 06; 38(10):847-851. PubMed ID: 38976087
    [Abstract] [Full Text] [Related]

  • 18. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug 06; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb 06; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and Evaluation of 99mTc-Labeled DPro-Gly-Containing Tracers Targeting PSMA.
    Li Z, Jiang Y, Ruan Q, Yin G, Han P, Duan X, Zhang J.
    Mol Pharm; 2024 Oct 07; 21(10):5305-5314. PubMed ID: 39298677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.